Compositions and methods for inhibiting BMP

US10513521B2 · kind B2 · utility

Assignees

• The Brigham and Women's Hospital, Inc. · US
• University of Houston System · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Arthur Lee · San Jose, US
• John C. McKew · Ames, US
• Paresma R. Patel · Rockville, US
• Paul B. Yu · Boston, US
• Agustin H. Mohedas · Somerville, US
• Philip E. Sanderson · Bethesda, US
• Gregory D. Cuny · Houston, US
• Wei Zheng · Rockville, US
• Xiuli Huang · Potomac, US

Key dates

• Filing date: Jul 14, 2015
• Grant date: Dec 24, 2019
• Expiry date: Jul 14, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides bicyclic heteroaryl inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. Exemplary compounds include those of Formula I:These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.